OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BVC$14.8059

Batm Advanced Communications Ltd

Biotechnology & Medical ResearchVerified

Batm Advanced Communications Ltd has a liquidity position characterized by a current ratio of 1.85 and a price-to-book ratio of 76.76, indicating a strong equity position relative to its liabilities. The company's free cash flow of 6.52 million USD suggests it is generating positive cash from operations after capital expenditures, despite a negative operating cash flow of -6.97 million USD. The company's profitability is weak, with a net loss of 18.34 million USD and a negative return on equity of -27.96%. This contrasts with the industry's preferred metrics, which typically emphasize strong returns and positive net income. The operating income of 13.48 million USD is a positive figure, but it is insufficient to offset the company's overall losses. Batm's revenue is split between its Telecommunications and BATM Medical divisions, with the latter focusing on emerging markets in Eastern Europe and Asia. The company's geographic exposure is not fully disclosed, but its focus on developing countries suggests potential revenue concentration in these regions. The company's growth trajectory is mixed. While the current fiscal year shows a revenue of 123.198 million USD, the outlook for the next fiscal year is uncertain. Analysts have estimated a mean revenue of 95.1 million USD, which is lower than the current year's actual revenue. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative net income and high price-to-book ratio suggest potential financial instability. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events include a negative EPS of -3.94 USD and a mean EPS estimate of 0.00 USD, indicating a challenging earnings outlook. The company's ESG controversies score is 100.0, suggesting significant environmental, social, and governance issues.

30-day price · BVC+0.95 (+7.3%)
Low$12.55High$15.35Close$13.95As of10 May, 00:00 UTC
Profile
CompanyBatm Advanced Communications Ltd
TickerBVC.L
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Batm Advanced Communications Ltd operates in the development, production, and marketing of medical and data communication products, with two divisions: Telecommunications and BATM Medical.

Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a confidence level of 0.92.

Batm Advanced Communications Ltd has a liquidity position characterized by a current ratio of 1.85 and a price-to-book ratio of 76.76, indicating a strong equity position relative to its liabilities. The company's free cash flow of 6.52 million USD suggests it is generating positive cash from operations after capital expenditures, despite a negative operating cash flow of -6.97 million USD. The company's profitability is weak, with a net loss of 18.34 million USD and a negative return on equity of -27.96%. This contrasts with the industry's preferred metrics, which typically emphasize strong returns and positive net income. The operating income of 13.48 million USD is a positive figure, but it is insufficient to offset the company's overall losses. Batm's revenue is split between its Telecommunications and BATM Medical divisions, with the latter focusing on emerging markets in Eastern Europe and Asia. The company's geographic exposure is not fully disclosed, but its focus on developing countries suggests potential revenue concentration in these regions. The company's growth trajectory is mixed. While the current fiscal year shows a revenue of 123.198 million USD, the outlook for the next fiscal year is uncertain. Analysts have estimated a mean revenue of 95.1 million USD, which is lower than the current year's actual revenue. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative net income and high price-to-book ratio suggest potential financial instability. The dilution potential is low, and no adjustments have been applied to the valuation metrics. Recent events include a negative EPS of -3.94 USD and a mean EPS estimate of 0.00 USD, indicating a challenging earnings outlook. The company's ESG controversies score is 100.0, suggesting significant environmental, social, and governance issues.
Key takeaways
  • Batm Advanced Communications Ltd has a strong equity position but is experiencing a net loss.
  • The company's profitability is weak, with a negative return on equity and net income.
  • Revenue is split between two divisions, with a focus on emerging markets.
  • The company's growth outlook is uncertain, with analysts forecasting lower revenue.
  • The risk assessment indicates low liquidity and dilution risks, but the company faces significant ESG controversies.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's margin outlook is negative due to a net loss and weak profitability.
  • **rd_outlook_rationale**: The R&D outlook is not explicitly provided, but the company's focus on development suggests ongoing investment.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$123.2M
Gross profit$40.1M
Operating income$13.5M
Net income-$18.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$7.0M
CapEx-$4.3M
Free cash flow$6.5M
Total assets$113.8M
Total liabilities$48.3M
Total equity$65.6M
Cash & equivalents$22.9M
Long-term debt$10.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$14.80
Market cap$5.03B
Enterprise value$5.02B
P/E
Reported non-GAAP P/E
EV/Revenue40.8
EV/Op income372.5
EV/OCF
P/B76.8
P/Tangible book76.8
Tangible book$65.6M
Net cash$12.5M
Current ratio1.9
Debt/Equity0.2
ROA-16.1%
ROE-28.0%
Cash conversion38.0%
CapEx/Revenue-3.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
MetricBVCActivity
Op margin10.9%-2.9% medp25 -218.9% · p75 9.6%top quartile
Net margin-14.9%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin32.5%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-3.5%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity16.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean EPS estimate0.00 USD
Last actual EPS-3.94 USD
Mean revenue estimate95,100,000 USD
Last actual revenue123,198,000 USD
Mean EBIT estimate-800,000.00 USD
market data ESG controversies score100.0
market data ESG governance pillar86.2
market data ESG social pillar47.0
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 05:46 UTC#c6b9c0ae
Market quoteclose USD 14.80 · shares 0.34B diluted
no public URL
2026-05-10 05:46 UTC#3ab42ae1
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 05:48 UTCJob: 311c9c00